AI Article Synopsis
- Previous studies found that vaccinating high-risk heterosexuals with a combo hepatitis A/B vaccine was cost-effective compared to just vaccinating against hepatitis B.
- The incidence of hepatitis A in the U.S. has decreased significantly since those studies.
- New estimates show that offering the combined vaccine now costs about $120,000 per quality-adjusted life year, making it less financially favorable compared to several other vaccination strategies.
Article Abstract
Previous studies estimated that vaccinating high-risk heterosexuals (HRH) with combination hepatitis A/B vaccine was a cost-effective alternative to vaccinating HRH against hepatitis B alone. Since then, the incidence of hepatitis A has declined dramatically in the United States. We re-estimate the cost-effectiveness of this policy accounting for modern declines in incidence. According to our estimates, vaccinating with combination vaccine resulted in a cost of $120,000 per quality adjusted life year gained (2.79 times the 2005 United States Gross Domestic Product per capita), a ratio that is less favorable than those for most other vaccination strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2008.07.089 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!